Connect with us

Stock Market Breaking News

XSport Global Inc. (XSPT) Enters into $1,000,000 Equity Purchase Agreement with TRITON FUNDS, LP

Joe Samuel

Published

on

Charlotte, NC, Nov. 01, 2018 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — XSport Global, Inc. (OTCQB: XSPT) (“XSport Global” or the “Company”), a leading youth and collegiate sports technology and media holding company focused on developing disruptive sports-centric technologies and related media projects around the world, today announced the Company has entered into an equity purchase agreement with TRITON FUNDS, LP (“TRITON FUNDS” or “Investor”).

The agreement is for the purchase of the company’s common stock in the amount up to $1,000,000 at the sole discretion of XSport Global. The closing for Capital Call Shares shall occur on the date that is six business days following the date that the Investor receives Capital Call Shares from the Company. The purchase price for the shares to be paid by the Investor at each closing, having a discount of 30% of the volume-weighted average price of the Company’s common stock during the 5 trading days prior to a closing date. Neither the Investor, nor any affiliate of the Investor acting on its behalf, will execute any Short Sales during the commitment period.

“Receiving the vote of confidence from TRITON FUNDS, acknowledges XSport Global’s disruptive sports-centric, scientific product offerings and overall business potential,” stated Robert Finigan, Chief Executive Officer of XSport Global. “This funding will allow us to: develop new product offerings, explore additional acquisitions, acquire talent and invest in marketing and sales, as we grow to be a global business and leader in the Sports category.”

Yash Thukral, Founder, of TRITON FUNDS, said, “We continue to seek out the best investment opportunities and XSport Global represents the type of early-stage, growth company we intend to add to our portfolio of investments. We believe their business acumen and strategy is sound, and we are confident with the tremendous upside potential in the multi-billion dollar cognitive sports training industry. We look forward to working together.”

“A management team that is highly motivated in seeing through the Company’s vision is something we here at TRITON FUNDS highly emphasize, and Robert Finigan provided just that for XSPT,” added Dmitriy Slobodskiy, Junior Partner, of TRITON FUNDS. “As a millennial fund, we pride ourselves in working with companies such as XSport Global who directly affect our generation as well as the youth in providing new technology and insight in an ever-changing space.”

About TRITON FUNDS:

TRITON FUNDS was started by three undergraduate students from Southern California aspiring to create an investment fund with a millennial touch. Our journey began on the streets of La Jolla, California in search of investors willing to back our idea of a student-run fund that creates a greater sense of community through investments in local companies and entrepreneurs, philanthropy, and guidance to fellow college students interested in the finance field. As a result, local limited partners, coupled with the support of our advisory board, helped us establish TRITON FUNDS, creating real-world opportunities for college students to invest in growing companies.

About XSport Global, Inc.

XSport Global, Inc. (OTCQB: XSPT) is a leading youth and collegiate sports technology and media holding company focused on developing disruptive sports-centric technologies and related media projects around the world, where sports industries and players are highly regarded. Backed by a roster of professional athletes and brand ambassadors, we seek to help athletes achieve their full potential through cognitive training, careers, genetics, recruiting and more. Our flagship company HeadTrainer, Inc was established to create, develop, promote, market, produce, and distribute online/mobile application cognitive training tools initially intended for the youth, millennial, and adult sports markets. The mobile platform was designed and developed in careful coordination with a team of professionals from the fields of science and medicine, and world-class athletes from a variety of sports. Visit www.xsportglobal.com and www.headtrainer.com for more information.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995.

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. You can identify forward-looking statements by words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “should,” “would” or similar words. You should consider these statements carefully because they discuss our plans, targets, strategies, prospects and expectations concerning our business, operating results, financial condition and other similar matters. These statements are subject to certain risks, uncertainties, and assumptions, including, but not limited to, risks and uncertainties relating to the Company’s ability to develop, market and sell products and services, based on its technology; the expected benefits and efficacy of the Company’s products, services and technology; the availability of additional funding for the Company to continue its operations and to conduct research and development, and future product commercialization; and, the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies; the ability of the Company to execute on a business plan that permits the technologies and innovations businesses to provide sufficient growth, revenue, liquidity and cash flows for sustaining the Company’s go-forward business, and the risks identified and discussed under the caption “Risk Factors” in the XSport Global Annual Report filed with the Securities and Exchange Commission (the “SEC”) and the other documents XSport Global files with the SEC from time to time. There will be events in the future, however, that XSport Global is not able to predict accurately or control. XSport Global’s actual results may differ materially from the expectations that XSport Global describes in its forward-looking statements. Factors or events that could cause XSport Global’s actual results to materially differ may emerge from time to time, and it is not possible for XSport Global to accurately predict all of them. Any forward-looking statement made by XSport Global in this press release speaks only as of the date on which XSport Global makes it. XSport Global undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

DISCLAIMER: Pursuant to an agreement between MIDAM VENTURES, LLC an affiliate of JSG COMMUNICATIONS LLC and XSport Global, Inc. we were hired for a period from 11/4/2018 – 12/4/2018 to publicly disseminate information about XSport Global, Inc. including on the Website and other media including Facebook and Twitter. We were paid $50,000 (CASH) for & were paid “0” shares of restricted common shares. We own zero shares of XSport Global, Inc., which we purchased in the open market. We may buy or sell additional shares of XSport Global, Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Click Here For Full Disclaimer

Continue Reading
Click to comment

Featured

ParcelPal (PTNYF) (PKG) Announces Delivery Agreement with Aphria Inc. (APHA)

Joe Samuel

Published

on

defense industry merger

VANCOUVER, British Columbia , Aug. 22, 2019 /CNW/ — ParcelPal Technology Inc. (“ParcelPal” or the “Company”), (PKG.CN) (PT0.F) (PTNYF) is pleased to announce that it secured a distribution agreement with one of the largest Canadian Federally Licensed producers in Canada , Aphria Inc. (“Aphria”) (APHA.TO) (APHA) for delivery of medical cannabis to patients.

This initiative between ParcelPal and Aphria will commence with Calgary as the catalyst city. Patients can purchase product from Aphria’s online store and utilize the ParcelPal technology platform to receive their product safely and legally. All customers will be able to track their purchase in real time and have their product delivered directly to any location they specify within Calgary .

In collaboration with ParcelPal, and MADD Canada are confident that this program will not only enable consumers unfettered access to their medicinal cannabis in a safe and timely manner but will furthermore assist in eliminating impaired drivers from our roadways by removing their need to drive to or from cannabis stores for product.

ParcelPal expects that additional cities will be rapidly added to its distribution network across Canada . As time and regulations allow, ParcelPal’s cannabis network will continue to grow, with the goal of capturing a major piece of Canada’s $4.0B legal cannabis market.

President and CEO, Kelly Abbott states, “The legal cannabis space continues to serve as a sector filled with significant growth potential for ParcelPal. Management believes that we are launching our legal cannabis delivery platform at the ideal time as legislation across the country continues to expand the addressable cannabis marketplace and we are thrilled to be working with Aphria on this exciting new venture that will help to kick off the next evolution of our company. We expect to leverage numerous business opportunities in the upcoming year. We look forward to establishing ourselves as a market leader in the cannabis delivery space and capturing meaningful market share in 2019 and beyond.”

About ParcelPal Technology Inc.

ParcelPal is a technology-driven logistics company that connects consumers to the goods they love. Customers can shop at partner businesses and through the ParcelPal technology receive their purchased goods within an hour. The Company offers on-demand delivery of merchandise from leading retailers, restaurants, marijuana dispensaries and liquor stores in Vancouver and soon in major cities Canada -wide.

ParcelPal Website: www.parcelpal.com

The Canadian Securities Exchange (“CSE”) or any other securities regulatory authority has not reviewed and does not accept responsibility for the adequacy or accuracy of this news release that has been prepared by management.

CSE – Symbol: PKG
FSE – Symbol: PT0
OTC – Symbol: PTNYF

Forward Looking Information.

We seek safe harbour.

This news release contains forward looking statements relating to the Proposed Transaction, and the future potential of ParcelPal. Forward looking statements are often identified by terms such as “will”, “may”, “should”, “intends”, “anticipates”, “expects”, “plans” and similar expressions. All statements other than statements of historical fact, included in this release are forward looking statements that involve risks and uncertainties. These risks and uncertainties include, without limitation, the risk that the Proposed Transaction will not be completed due to, among other things, failure to execute definitive documentation, failure to complete satisfactory due diligence, failure to receive the approval of the CSE and the risk that ParcelPal will not be successful due to, among other things, general risks relating to the mobile application industry, failure of ParcelPal to gain market acceptance and potential challenges to the intellectual property utilized in ParcelPal. There can be no assurance that any forward looking statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements.

The Company cannot guarantee that any forward looking statement will materialize and the reader is cautioned not to place undue reliance on any forward looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward looking statements contained in this news release are expressly qualified by this cautionary statement. The forward looking statements contained in this news release are made as of the date of this news release and the Company will only update or revise publicly any of the included forward looking statements as expressly required by Canadian securities laws.

Contact:
Peter Hinam
Investor Relations
peter@parcelpal.com
+1-604-401-8700

View original content on PRNewswire.com: http://www.prnewswire.com/news-releases/parcelpal-announces-delivery-agreement-with-aphria-inc-300905818.html

MIDAM VENTURES LLC has been compensated $75,000 per month by a ParcelPal Technology, Inc. for a period beginning September 1, 2018 and ending February 1, 2019 to publicly disseminate information about (PTNYF/PKG) to publicly disseminate information about (PTNYF/PKG). Midam Ventures has been compensated $100,000 by Parcel Pal and has extended coverage to April 1, 2019. Midam Ventures has been compensated $100,000 by Parcel Pal and has extended coverage to May 1, 2019. Midam Ventures has been compensated $200,000 by Parcel Pal and has extended coverage to June 1, 2019. Midam Ventures has been compensated $200,000 by Parcel Pal and has extended coverage to July 1, 2019. We may buy or sell additional shares of (PTNYF/PKG) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. We own zero shares. Read Full Disclaimer Here

Continue Reading

Biotechnology

PharmaCyte Biotech to Hold Special Shareholder Meeting

A. Lawrence

Published

on

biotechnology stock price

LAGUNA HILLS, Calif.–(BUSINESS WIRE)–

PharmaCyte Biotech, Inc. (PMCB), a clinical-stage biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that it will hold a Special Shareholder Meeting on September 11, 2019. The shareholder meeting, not to be confused with a shareholder conference call, will be held at the Courtyard by Marriott in Irvine, California, and will begin at 11:00 a.m. Pacific Daylight Time.

During the meeting there will be an update on PharmaCyte’s current research-related projects followed by a question and answer session regarding the update. The meeting will then turn to management matters, such as: (i) amending PharmaCyte’s Articles of Incorporation to provide the Board of Directors (“Board”) the power to designate the rights and preferences of PharmaCyte’s preferred stock; (ii) election of six directors as nominated by the Board’s Nominating Committee and approved by the Board, each to serve a one-year term; (iii) ratification of the appointment of Armanino LLP as PharmaCyte’s independent registered public accounting firm for the fiscal year ending April 30, 2020 and (iv) to consider and act upon any other business as may properly come before the Special Shareholder Meeting.

PharmaCyte’s Chief Executive Officer, Kenneth L. Waggoner, stated, “This shareholder meeting will be the first during my tenure as CEO. Since the new management team took over in 2014, we have faced untold challenges and hurdles virtually every day. We have persevered. We believe we’re on the brink of a new dawn for the company as we work collaboratively with so many stellar professional colleagues to showcase the unique Cell-in-a-Box® technology in which so many have worked so diligently over the past several years. We feel that it is important to realize our full potential while, at the same time, bringing value to and protecting our shareholders who have stood by us for so long.

“We look forward to meeting many of our long-standing and new shareholders who can attend and in implementing the steps that will enable us to succeed on numerous fronts.”

About PharmaCyte Biotech:

PharmaCyte Biotech is a clinical stage biotechnology company developing cellular therapies for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as “Cell-in-a-Box®.” This technology will be used as a platform upon which therapies for several types of cancer and diabetes are being developed.

PharmaCyte’s therapy for cancer involves encapsulating genetically engineered human cells that convert an inactive chemotherapy drug into its active or “cancer-killing” form. For pancreatic cancer, these encapsulated cells are implanted in the blood supply to the patient’s tumor as close as possible to the site of the tumor. Once implanted, a chemotherapy drug that is normally activated in the liver (ifosfamide) is given intravenously at one-third the normal dose. The ifosfamide is carried by the circulatory system to where the encapsulated cells have been implanted. When the ifosfamide flows through pores in the capsules, the live cells inside act as a “bio-artificial liver” and activate the chemotherapy drug at the site of the cancer. This “targeted chemotherapy” has proven effective and safe to use in past clinical trials and results in little to no treatment related side effects.

PharmaCyte’s therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes involves encapsulating a human cell line that has been genetically engineered to produce, store and release insulin in response to the levels of blood sugar in the human body. PharmaCyte is exploring the use of genetically modified liver cells, stem cells and beta islet cells. The encapsulation will be done using the Cell-in-a-Box® technology. Once the encapsulated cells are implanted in a diabetic patient, they will function as a “bio-artificial pancreas” for purposes of insulin production.

Safe Harbor

This press release contains forward-looking statements, which are generally statements that are not historical facts. Forward-looking statements can be identified by the words “expects,” “anticipates,” “believes,” “intends,” “estimates,” “plans,” “will,” “outlook” and similar expressions. Forward-looking statements are based on management’s current plans, estimates, assumptions and projections, and speak only as of the date they are made. We undertake no obligation to update any forward-looking statement because of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Actual results or outcomes may differ materially from those implied by the forward-looking statements due to the impact of numerous risk factors, many of which are discussed in more detail in our Annual Report on Form 10-K and our other reports filed with the Securities and Exchange Commission.

More information about PharmaCyte Biotech can be found at www.PharmaCyte.com. Information may also be obtained by contacting PharmaCyte’s Investor Relations Department.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190821005275/en/

Contact:
Dr. Gerald W. Crabtree
Investor Relations:
PharmaCyte Biotech, Inc.
Investor Relations Department
Telephone: 917.595.2856
Email: Info@PharmaCyte.com

Disclaimer: Pursuant to an agreement between MIDAM VENTURES, LLC and Complete Investment And Management LLC, a Non-affiliate Third Party, Midam was hired for a period from 07/09/2019 – 8/09/2019 to publicly disseminate information about PharmaCyte Biotech including on the Website and other media including Facebook and Twitter. We were paid $150,000 (CASH) for & were paid “0” shares of restricted common shares. We were paid an additional $150,000 (CASH) BY Complete Investment And Management LLC, a Non-affiliate Third Party, AND HAVE EXTENDED coverage for a period from 8/12/2019 – 9/12/2019. We may buy or sell additional shares of PharmaCyte Biotech in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Click Here For Full Disclaimer

Continue Reading

Featured

Stock Price Wednesday Morning Update – August 21, 2019

Joe Samuel

Published

on

biotech stocks to watch

PharmaCyte Biotech to Hold Special Shareholder Meeting

PharmaCyte Biotech, Inc. (PMCB), a clinical-stage biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that it will hold a Special Shareholder Meeting on September 11, 2019.

See More On This – CLICK HERE


Must Read Biotech Stock Report

With a wave of groundbreaking products in the pipeline, biotechnology could be poised to keep churning higher for the foreseeable future. But how can you get in on the ground floor of the next big wave in biotech?

Continue Reading


2 Food Delivery Stocks To Watch Before The End Of Summer

The food delivery industry in the United States has grown into a behemoth and although the margins are extremely thin, investors are willing to bet billions on some of the biggest food delivery companies. At this point in time, companies are fighting among themselves to gain supremacy in this space and competition is heating up as they look to grab market share from each other.

Read More Here


2 Chinese Stocks Making Bullish Moves

The trade war with the United States and an economic slowdown for the first time in three decades has cratered the markets in China. China-based stocks have generally underperformed over the course of the past year. But even during such a slowdown, some stock prices have been showing bullish tendencies. Here is a look at two such China-based companies that have seen stock prices climb.

See For Yourself

biotech stock to buy 2019

Disclaimer: Pursuant to an agreement between MIDAM VENTURES, LLC and Complete Investment And Management LLC, a Non-affiliate Third Party, Midam was hired for a period from 07/09/2019 – 8/09/2019 to publicly disseminate information about PharmaCyte Biotech including on the Website and other media including Facebook and Twitter. We were paid $150,000 (CASH) for & were paid “0” shares of restricted common shares. We were paid an additional $150,000 (CASH) BY Complete Investment And Management LLC, a Non-affiliate Third Party, AND HAVE EXTENDED coverage for a period from 8/12/2019 – 9/12/2019. We may buy or sell additional shares of PharmaCyte Biotech in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Click Here For Full Disclaimer

Continue Reading

Join Our Newsletter

Get stock alerts, news & trending stock alerts straight to your inbox!


We keep all user information pricate & promise to never spam.*

Privacy Policy

Search Stock Price (StockPrice.com)




Trending

Subscribe Now & Begin Receiving Free Stocks News, Articles, Trade Alerts & MORE, all 100% FREE!

We are your #1 source for all things Stock Market & Finance, Subscribe Below!

Privacy Policy: We will NEVER share, sell, barter, etc. any of our subscribers information for any reason ever! By subscribing you agree we can send you via email our free e-newsletter on stock market & finance related, articles, news and trade alerts. Further questions please contact privacy@stockprice.com